New real-world data published on November 12, 2024, in the Journal of Clinical Oncology - Oncology Practice (JCO-OP) by Providence, Illumina, and Microsoft Research, demonstrated that Comprehensive Genomic Profiling (CGP) significantly improves personalized treatment and patient outcomes when performed early in a cancer diagnosis.
The study found that CGP identified actionable mutations in 67% of tumors, compared to only 33% with small-panel tests. This led to 52% of CGP-tested patients receiving matched targeted therapy or immunotherapy, as opposed to 32% of patients who received conventional systemic chemotherapy alone.
Patients who received a targeted therapy based on CGP results showed significantly better overall survival, with a median of 25 months compared to 17 months for those treated with chemotherapy alone. These findings underscore the importance of integrating CGP into standard diagnostic practices to guide precision treatments and improve patient survival.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.